Bleeding episodes

Drug	Drug Name	Drug Description
DB13884	Albutrepenonacog alfa	A recombinant Factor IX fused to recombinant human albumin used to treat hemophilia B.
DB16662	Efanesoctocog alfa	A recombinant DNA-derived, Factor VIII concentrate indicated for routine prophylaxis, on-demand treatment and control of bleeding episodes, and perioperative management of bleeding in patients with hemophilia A.

Drug	Drug Name	Target	Type
DB13884	Albutrepenonacog alfa	Coagulation factor X	target
DB13884	Albutrepenonacog alfa	Coagulation factor VIII	enzyme
DB16662	Efanesoctocog alfa	Low-density lipoprotein receptor-related protein 2	target
DB16662	Efanesoctocog alfa	Basement membrane-specific heparan sulfate proteoglycan core protein	target
DB16662	Efanesoctocog alfa	Coagulation factor IX	target
DB16662	Efanesoctocog alfa	Coagulation factor X	target

Drug	Drug Name	Phase	Status	Count